AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and effectiveness of upadacitinib, an oral medication, in treating moderate to severe hidradenitis suppurativa (HS) in patients who have not responded to anti-TNF therapy. This study is significant as it targets a challenging condition with limited treatment options.

The intervention being tested is upadacitinib, an oral tablet already approved for several inflammatory conditions. It is being evaluated for its potential to treat HS, offering hope for patients with limited alternatives.

The study is interventional with a randomized, parallel assignment model. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment assignments. The primary purpose is treatment-focused, aiming to determine the drug’s efficacy and safety.

The study began on June 21, 2023. The primary completion and estimated completion dates are not specified, but the last update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

This study update could positively influence AbbVie’s stock performance and investor sentiment, as successful results may lead to a new treatment option for HS, potentially expanding the market for upadacitinib. Investors should also consider the competitive landscape, as advancements in HS treatment could impact other companies in the dermatology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.